In December 2025, J.P. Morgan upgraded Recursion Pharmaceuticals after REC-4881 showed rapid, durable polyp burden reductions and a favorable safety profile in familial adenomatous polyposis patients, ...

Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...

Former Google CEO Eric Schmidt declared his own programming expertise obsolete after watching an AI system autonomously ...

Here are the top 16 conferences to mark on your 2026 calendar for technologists, business leaders, policy experts, and those ...

A new research paper reframes the simulation hypothesis, asking whether reality could be simulated and what science can test.

Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies ...

Fruchter, G. (2026) Opportunism in Supply Chain Recommendations: A Dynamic Optimization Approach. Modern Economy, 17, 26-38.

Takeda regains a majority of XOMA Royalty’s royalty interest in mezagitamab (TAK-079) –– XOMA Royalty will be entitled to payments based on a ...

Takeda regains a majority of XOMA Royalty's royalty interest in mezagitamab (TAK-079) -- XOMA Royalty will be entitled to payments based on a share of milestones and royalties associated with nine ...